XVR011, our lead compound is a potent, broadly neutralising SARS-COV-2 antiviral treatment. XVR011, an enhanced version of VHH72-FC, binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. It offers breadth and potency against a range of Sabecoviruses and is not impacted in its binding affinity to, or neutralising capacity of circulating SARS-CoV-2 Variants Of Concern.
VHH are single-domain antibody fragments derived from camelids, they are smaller than human antibodies and can attach to parts of a virus that are difficult to access for the human immune system. Stopping infection and viral replication supports the patient’s immune response by reducing the viral load and dampening local and systemic inflammation. This is particularly beneficial for those at increased risk of severe illness from COVID-19.
XVR011, in clinical stage Phase 1b, is in accelerated development as a therapeutic and holds potential as a prophylactic to ringfence outbreaks.
XVR011 maintains in vitro neutralization activity against SARS-CoV-2 Variants of Concern, as well as the current Variants of Interest.
- Based on its epitope sequence, no impact of any currently circulating Variant of Concern of Variant of Interest predicted
- XVR011 demonstrated strong in vitro neutralization potency against the Variants of Concern Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Gamma (P.1). These data were generated in the laboratory of Professor Johan Neyts at the Rega institute (KU Leuven, Belgium)